Astellas Pharma Inc. and PeptiDream Inc.today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. Under the

Cybin Inc.company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that its Phase 2 trial

ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced

BeiGene a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion

SunHo BioPharmaceutical Co., Ltd.a clinical-stage leading biopharmaceutical company in immunocytokines with full-set of capabilities from discovery to commercialization, announced

MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients

Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Approved for Public Release, Distribution Unlimited — The Defense Advanced Research Projects Agency (DARPA) announced that Ginkgo Bioworks which is building

Gannex Pharma Co., Ltd. a wholly-owned company of Ascletis Pharma Inc.announces today the completion of enrollment of 98 patients with primary biliary cholangitis

Santen Pharmaceutical Co.,Ltd.announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.